TABLE 4.

Office and ambulatory blood pressures measured after 1 month of placebo or empagliflozin 10 mg in normotensive subjects.

	Placebo (n = 13)				Empagliflozin 10 mg (n = 26)				Placebo vs. Empa
Clinical	Baseline T0(AP)	1 month T0(CP)	Delta	P value	Baseline T0(AP)	1 month T0(CP)	Delta	P-value	P-value
Weight (kg)	88.9 ± 22.8	89.2 ± 22.8	+ 0.3 ± 0.9	0.3	87.8 ± 17.4	87.4 ± 17.8	−0.5 ± 1.9	0.2	0.2
Office SBP (mmHg)	118 ± 10	120 ± 10	+ 2 ± 11	0.6	120 ± 12	116 ± 14	−4 ± 12	0.05	0.08
Office DBP (mmHg)	72 ± 9	71 ± 10	−1 ± 7	0.6	74 ± 11	71 ± 9	−3 ± 11	0.2	0.6
Pulse (bpm)	61 ± 10	60 ± 7	−2 ± 6	0.4	63 ± 9	65 ± 11	+2 ± 12	0.4	0.3
24 h BP measurements
24 h SBP (mmHg)	112 ± 8	115 ± 11	+ 3 ± 6	0.1	117 ± 9	112 ± 9	−5 ± 7	0.0003	0.0005
Day SBP (mmHg)	115 ± 10	117 ± 10	+ 1 ± 7	0.5	120 ± 10	116 ± 8	−4 ± 8	0.01	0.03
Night SBP (mmHg)	103 ± 9	108 ± 13	+ 5 ± 13	0.2	108 ± 11	102 ± 10	−6 ± 11	0.004	0.004
24 h DBP (mmHg)	72 ± 7	73 ± 8	+ 2 ± 4	0.2	73 ± 6	71 ± 6	−2 ± 6	0.04	0.03
Day DBP (mmHg)	74 ± 8	75 ± 8	+ 1 ± 5	0.4	76 ± 7	75 ± 7	−1 ± 7	0.5	0.3
Night DBP (mmHg)	65 ± 8	66 ± 10	+ 1 ± 7	0.6	67 ± 8	63 ± 8	−4 ± 7	0.007	0.03
24 h heart rate (bpm)	74 ± 12	73 ± 13	−2 ± 10	0.6	76 ± 8	74 ± 8	−7 ± 10	0.4	0.9
Day heart rate (bpm)	79 ± 13	77 ± 14	−2 ± 11	0.5	79 ± 9	79 ± 9	−0 ± 11	0.9	0.5
Night heart rate (bpm)	63 ± 10	62 ± 11	−1 ± 8	0.7	66 ± 10	63 ± 8	−3 ± 13	0.3	0.6